Pushing the boundaries
At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness
ABC Platform
At Kodiak, we are developing disruptive products and platforms to prevent and treat leading causes of blindness
Generation 2.0 Retinal Medicines
Antibody biopolymer conjugates are intended to be:
Same Where It Matters
- Clinically proven targets
- Antibody-based biologic
- Intravitreal: safest method of administration
- Optically clear, no residues
- Fast and potent clinical responses
Different Where It Counts
- Designed-in ocular durability
- Designed-in rapid systemic clearance
- Improved bioavailability
- Improved biocompatibility
- Improved stability
Go Big, Not Small
Size
In general, the larger the size, the longer the molecule will remain in the eye.
Drug per dose
Drug per dose is how many target binding units fit into the injected clinical dose.
Ocular half-life
Ocular half-life is how long the drug lasts in the eye which is a key driver of durability.
More than the sum of its parts
The ABC Platform is designed to improve durability while structuring water at critical binding interfaces for improved specificity, affinity and tissue access
Remarkable Intraocular Half-life
Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentration levels in the eye
Excellent Retinal Bioavailability
Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentrations in the eye
Fast Systemic Clearing
The ABC Platform is designed to clear the body quickly after it exits from the eye.
REVOLUTIONIZING TREATMENT OF MULTIFACTORIAL RETINAL DISEASES WITH TRIPLET MEDICINES
Our triplet medicines combine the benefits of our ABC platform with the sustained release of small molecules to target three mechanisms of action enabling treatment of complex diseases such as dry AMD.